LataMed AI Corp. (OTC: LMED), a digital health and artificial intelligence technology company focusing on telehealth infrastructure and healthcare analytics for emerging markets, announced that it expects to formally submit a corporate action request to FINRA today seeking approval of a proposed five-for-one forward stock split. The proposal also includes proportional increases in the company’s authorized common stock and preferred stock.
The proposed forward stock split would apply proportionally to all issued and outstanding shares of common stock and outstanding preferred stock designations, including the Series C Voting Preferred Stock. The company stated that the split is intended to support broader long-term operational scalability, strategic flexibility, capitalization planning, and future growth initiatives as it continues advancing telehealth infrastructure deployment, healthcare analytics integration, regulatory progression, and commercialization initiatives throughout Latin America and other targeted emerging markets.
Management emphasized that the proposed corporate action does not involve any debt restructuring, recapitalization, or reduction in shareholder ownership percentages. No fractional shares are expected to be issued, as any fractional interests would be rounded up to the nearest whole share pursuant to approved board resolutions.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated: “As we continue advancing our operational and commercialization initiatives throughout Latin America, we believe this proposed forward stock split and proportional capital structure expansion may support broader long-term strategic flexibility, operational scalability, and future growth initiatives as we continue building our healthcare technology platform.”
The company recently announced the commencement of initial operational activities associated with its telehealth platform infrastructure in Venezuela following receipt of regulatory authorization through the Ministerio del Poder Popular para la Salud and Servicio Autonomo de Contraloria Sanitaria (SACS). This milestone marks a critical step in LataMed’s expansion strategy within Latin America, a region with significant demand for digital healthcare solutions.
The proposed forward stock split remains subject to FINRA review and approval, completion of applicable regulatory processing, and final corporate implementation procedures. No assurance can be provided regarding the timing or ultimate effectiveness of the proposed corporate action.
For more information, please visit https://latamed.ai, follow the company’s official Instagram page at https://www.instagram.com/latamedai, or review the company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
The forward stock split is a strategic move to align the company’s capital structure with its transition into digital healthcare infrastructure and AI-driven telehealth operations. As a development-stage enterprise that has not yet generated revenues from its current business operations, LataMed AI is positioning itself to participate in the modernization and digital transformation of healthcare delivery systems across emerging markets.
This announcement underscores the company’s commitment to scaling its operations and enhancing shareholder value as it navigates the complex regulatory and operational landscape of emerging markets. The approval of the forward stock split could provide the company with greater flexibility to pursue future growth opportunities, including potential partnerships, acquisitions, and further expansion of its telehealth platform.
